November 15, 2017
Ocular Surface Regeneration in Dry Eye Disease: New Article and Case Study
published on November 15, 2017 by
For patients with chronic dry eye disease causing corneal conditions such as SPK or filamentary keratitis, PROKERA® offers a viable option for immediate intervention as a powerful anti-inflammatory with the long-lasting benefit of regenerative healing.
PROKERA is the only cryopreserved amniotic membrane (CAM) graft that fastens to a polycarbonate ring system. As a self-retaining biologic corneal bandage that can be readily inserted in office, PROKERA is also the only FDA-cleared therapeutic tissue product available for wound healing of the ocular surface. Rich in biological factors such as HC-HA/PTX3 and nerve growth factor, PROKERA has been shown to exert potent anti-inflammatory action and facilitate ocular surface healing.1-3
We invite you to download a recently published article and case study by Neel R. Desai, MD. In this article, Dr. Desai discusses results from The Dry Eye Amniotic Membrane Study (DREAMS), which is a retrospective study across ten clinical sites, that demonstrates the ability of PROKERA to rapidly improve ocular surface health.4
Another preliminary retrospective study shows that PROKERA is effective in improving symptoms, restoring ocular surface integrity, and reducing the frequency of concomitant topical medications in moderate to severe DED.5
Dr. Desai also reviews a case of ocular surface optimization before cataract surgery. “The intervention with PROKERA turned someone not suitable for any type of cataract surgery into a candidate for refractive surgery.”
Are you incorporating our powerful technology to help you with challenging ocular surface conditions in your practice? Dr. Desai provides tips and pearls on his utilization of PROKERA in this attached article.